Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 6/20 | 0.38 |
| ▸ | CTSL | P07711 | 5/20 | 0.38 |
| ▸ | CTSS | P25774 | 5/20 | 0.38 |
| ▸ | METAP2 | P50579 | 3/20 | 0.35 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.35 |
| ▸ | REN | P00797 | 1/20 | 0.34 |
| ▸ | MME | P08473 | 1/20 | 0.32 |
| ▸ | ACE | P12821 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | XIAP | P98170 | 1/20 | 0.32 |
| ▸ | METAP1 | P53582 | 2/20 | 0.32 |
| ▸ | NAAA | Q02083 | 1/20 | 0.32 |
| ▸ | CTSC | P53634 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4310039 | 0.84 | CTSK (0.36) | CTSKCTSLCTSSXIAP | |
| SCHEMBL6212781 | 0.83 | CTSK (0.33) | CTSKCTSLCTSSALDH1A1KMT2A | |
| SCHEMBL4314936 | 0.78 | METAP2 (0.35) | CTSKMETAP2RENALDH1A1KMT2A | |
| SCHEMBL4314924 | 0.78 | METAP2 (0.35) | CTSKMETAP2RENALDH1A1KMT2A | |
| SCHEMBL4314933 | 0.78 | METAP2 (0.35) | CTSKMETAP2RENALDH1A1KMT2A | |
| SCHEMBL13784227 | 0.76 | CTSK (0.67) | CTSKCTSLCTSSALDH1A1 | |
| SCHEMBL13784228 | 0.76 | CTSS (0.46) | CTSKCTSLCTSS | |
| SCHEMBL5982743 | 0.73 | CTSK (0.45) | CTSKCTSLCTSSALDH1A1XIAP | |
| SCHEMBL4310035 | 0.73 | — | — | |
| SCHEMBL6744240 | 0.73 | CTSK (0.70) | CTSKCTSLCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060194787-A1 | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION | 2006-08-31 | — | — | US | claimed |
| EP-1307203-A4 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2005-08-17 | — | — | EP | claimed |
| US-20040229863-A1 | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION | 2004-11-18 | — | — | US | claimed |
| US-20040044201-A1 | Protease inhibitors | GLAXOSMITHKLINE LLC | 2004-03-04 | — | — | US | claimed |
| US-20030114437-A1 | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION | 2003-06-19 | — | — | US | claimed |
| EP-1307203-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-05-07 | — | — | EP | claimed |
| WO-2001070232-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-09-27 | — | — | WO | claimed |
| US-7563784-B2 | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2009-07-21 | — | — | US | disclosed |
| US-20060194787-A1 | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION | 2006-08-31 | — | — | US | disclosed |
| US-7071184-B2 | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2006-07-04 | — | — | US | disclosed |
| US-20040229863-A1 | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION | 2004-11-18 | — | — | US | disclosed |
| US-20040044201-A1 | Protease inhibitors | GLAXOSMITHKLINE LLC | 2004-03-04 | — | — | US | disclosed |
| US-20030114437-A1 | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION | 2003-06-19 | — | — | US | disclosed |
| EP-1278502-A4 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2003-05-21 | — | — | EP | disclosed |
| EP-1278502-A2 | PROTEASE INHIBITORS | SmithKline Beecham Corporation (US) | 2003-01-29 | — | — | EP | disclosed |
| WO-2001089451-A2 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030114437-A1 | Protease inhibitors | CTSS, CTSE, CTSF | CTSK 6/4885CTSL 24/4885CTSS 1/4885 |
| US-20060194787-A1 | Protease inhibitors | CTSK, CTSL, CTSZ | CTSK 1/4885CTSL 2/4885CTSS 4/4885 |
| US-20040044201-A1 | Protease inhibitors | CTSK, CTSE, CTSZ | CTSK 1/4885CTSL 11/4885CTSS 5/4885 |
| US-20040229863-A1 | Protease inhibitors | CTSS, CTSE, CTSF | CTSK 6/4885CTSL 24/4885CTSS 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.